Noncoding RNAs play important regulatory roles in diverse biological processes and their misregula-tion might lead to different diseases, including cancer. Previous studies have reported the evolving role of miR-NAs as new potential biomarkers in cancer diagnosis, prognosis, as well as predictive biomarkers of chemotherapy response or therapeutic targets. In this review, we outline the involvement of noncoding RNA in pancreatic cancer, providing an overview of known miRNAs in its diagnosis, prognosis and chemoresistance. In addition, we discuss the influence of non-coding RNAs in the metastatic behavior of pancreatic cancer, as well as the role of diet in epigenetic regulation of non-coding RNAs in cancer, which can, in turn, lead the development of new prevention’s techniques or novel targets for cancer therapy.

Noncoding RNAs emerging as novel biomarkers in pancreatic cancer / Garajova, I.; Balsano, R.; Tommasi, C.; Giovannetti, E.. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 24:39(2018), pp. 4601-4604. [10.2174/1381612825666190119125804]

Noncoding RNAs emerging as novel biomarkers in pancreatic cancer

Balsano R.;Tommasi C.;
2018-01-01

Abstract

Noncoding RNAs play important regulatory roles in diverse biological processes and their misregula-tion might lead to different diseases, including cancer. Previous studies have reported the evolving role of miR-NAs as new potential biomarkers in cancer diagnosis, prognosis, as well as predictive biomarkers of chemotherapy response or therapeutic targets. In this review, we outline the involvement of noncoding RNA in pancreatic cancer, providing an overview of known miRNAs in its diagnosis, prognosis and chemoresistance. In addition, we discuss the influence of non-coding RNAs in the metastatic behavior of pancreatic cancer, as well as the role of diet in epigenetic regulation of non-coding RNAs in cancer, which can, in turn, lead the development of new prevention’s techniques or novel targets for cancer therapy.
2018
Noncoding RNAs emerging as novel biomarkers in pancreatic cancer / Garajova, I.; Balsano, R.; Tommasi, C.; Giovannetti, E.. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 24:39(2018), pp. 4601-4604. [10.2174/1381612825666190119125804]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/3010313
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 3
social impact